AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31023257 — intervention group
Group type: EXPERIMENTAL
Intervention: AferBio®
Number of subjects: 10
Study 31023257 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 10
Study 28423480 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D3 (20,000 IU)
Number of subjects: 297
Study 28423480 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose vitamin D3 (800 IU)
Number of subjects: 297
Study 25567822 — intervention group
Group type: COMPARATOR
Intervention: Personalized mailed letters
Number of subjects: 0
Study 25567822 — intervention group
Group type: COMPARATOR
Intervention: Automated telephone calls
Number of subjects: 0
Study 25567822 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined (letter/automated call)
Number of subjects: 0
Study 23485070 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet cuff pressure of 237 (SD 33) mmHg
Number of subjects: 20
Study 23485070 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tourniquet cuff pressures
Number of subjects: 20
Study 21518220 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP) 200 mg twice daily or 400 mg once daily combined with tenofovir 300 mg/emtricitabine 200 mg once daily
Number of subjects: 569
Study 21518220 — intervention group
Group type: COMPARATOR
Intervention: Atazanavir/ritonavir (ATZ/r) 300 mg/100 mg once daily combined with tenofovir 300 mg/emtricitabine 200 mg once daily
Number of subjects: 569
Study 18350281 — intervention group
Group type: EXPERIMENTAL
Intervention: 333 mg Salvia extract
Number of subjects: 20
Study 18350281 — intervention group
Group type: EXPERIMENTAL
Intervention: 167 mg Salvia extract
Number of subjects: 20
Study 18350281 — intervention group
Group type: EXPERIMENTAL
Intervention: 666 mg Salvia extract
Number of subjects: 20
Study 18350281 — intervention group
Group type: EXPERIMENTAL
Intervention: 1332 mg Salvia extract
Number of subjects: 20
Study 18350281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 17068306 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA (intravenous recombinant tissue plasminogen activator)
Number of subjects: 0
Study 17068306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17068306 — intervention group
Group type: COMPARATOR
Intervention: Conventional inclusion criteria
Number of subjects: 0
Study 14535908 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (loading dose 1 microg x kg(‐1); maintenance infusion, 0.25 microg x kg(‐1) min(‐1))
Number of subjects: 60
Study 14535908 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil (loading dose 50 microg x kg(‐1); maintenance infusion, 1 microg x kg(‐1) min(‐1))
Number of subjects: 60
Study 11075771 — intervention group
Group type: EXPERIMENTAL
Intervention: ALM plus BCG
Number of subjects: 2306
Study 11075771 — intervention group
Group type: COMPARATOR
Intervention: BCG alone
Number of subjects: 2306
Study 8838433 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg once daily (increased to 10 mg if necessary)
Number of subjects: 34
Study 8838433 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 90 mg twice daily (increased to 180 mg if necessary)
Number of subjects: 34
Study 1442589 — intervention group
Group type: COMPARATOR
Intervention: Dietary fish oil
Number of subjects: 8
Study 3900155 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% topical minoxidil
Number of subjects: 126
Study 3900155 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% topical minoxidil
Number of subjects: 126
Study 3900155 — intervention group
Group type: COMPARATOR
Intervention: Placebo (initially) then crossed over to 3% topical minoxidil
Number of subjects: 126
Study 3793950 — intervention group
Group type: COMPARATOR
Intervention: Conventional quinidine sulfate 300 mg q6h
Number of subjects: 18
Study 3793950 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release quinidine sulfate 600 mg q12h
Number of subjects: 18
Study 3793950 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release quinidine gluconate 648 mg q12h
Number of subjects: 18
Study 29737513 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative complications
Number of subjects: 2856
Study 29737513 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive model for intraoperative complications
Number of subjects: 2856
Study 28322009 — intervention group
Group type: EXPERIMENTAL
Intervention: Worse left ventricular mechanical dyssynchrony (measured by SD T2P LS)
Number of subjects: 424
Study 26315829 — intervention group
Group type: EXPERIMENTAL
Intervention: 177Lu-EDTMP
Number of subjects: 32
Study 26315829 — intervention group
Group type: COMPARATOR
Intervention: 153Sm-EDTMP
Number of subjects: 32
Study 22593231 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light therapy
Number of subjects: 30
Study 21195290 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture on the point Sanyinjiao (SP6)
Number of subjects: 350
Study 21195290 — intervention group
Group type: COMPARATOR
Intervention: Sham electroacupuncture
Number of subjects: 350
Study 21195290 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 350
Study 18400351 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral motor activations of the approach and avoidance motivational systems
Number of subjects: 0
Study 16817580 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily activities (sitting, walking, running, jumping jacks, vertical leap, jumping off a step)
Number of subjects: 18
Study 14570661 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural bolus administration of fentanyl (0.03 mg followed by 0.1 mg 210 min later)
Number of subjects: 10
Study 14570661 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural infusion of fentanyl (0.03 mg/h followed by 0.1 mg/hr 210 min later for 200 min)
Number of subjects: 10
Study 14570661 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural infusion of fentanyl
Number of subjects: 10
Study 14570661 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural bolus administration of fentanyl
Number of subjects: 10
Study 10894961 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily repeated applications of moisturizers (twice daily for 5 days)
Number of subjects: 0
Study 8669676 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 351
Study 1563339 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurotol slow
Number of subjects: 21
Study 1563339 — intervention group
Group type: COMPARATOR
Intervention: Tegretol Retard
Number of subjects: 21
Study 4004715 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-loss treatment groups defined by homogeneity (similar gender and degree of overweight)
Number of subjects: 139
Study 4004715 — intervention group
Group type: COMPARATOR
Intervention: Weight-loss treatment groups defined by heterogeneity (dissimilar gender and degree of overweight)
Number of subjects: 139
Study 4004715 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with prior unsuccessful weight-loss experiences
Number of subjects: 139
Study 4004715 — intervention group
Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 139
Study 4004715 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavier individuals
Number of subjects: 139
Study 31699516 — intervention group
Group type: EXPERIMENTAL
Intervention: Second generation antipsychotics (AP); 92% of patients received this intervention; 74% received AP monotherapy; 79.5% received off-label AP prescriptions.
Number of subjects: 200
Study 31699516 — intervention group
Group type: EXPERIMENTAL
Intervention: First 3 months of treatment; noted as a significant period for AEs.
Number of subjects: 200
Study 28203808 — intervention group
Group type: EXPERIMENTAL
Intervention: Shamrock LPB
Number of subjects: 20
Study 28203808 — intervention group
Group type: COMPARATOR
Intervention: LUT LPB
Number of subjects: 20
Study 25863847 — intervention group
Group type: EXPERIMENTAL
Intervention: SF6 gas tamponade
Number of subjects: 59
Study 25863847 — intervention group
Group type: COMPARATOR
Intervention: C3F8 gas tamponade
Number of subjects: 59
Study 24048091 — intervention group
Group type: EXPERIMENTAL
Intervention: Local vancomycin powder in addition to systemic prophylaxis
Number of subjects: 907
Study 24048091 — intervention group
Group type: COMPARATOR
Intervention: Standard systemic prophylaxis only (Control)
Number of subjects: 907
Study 20837824 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (Actos), 45 mg daily, plus 200 IU of vitamin E daily
Number of subjects: 29
Study 20837824 — intervention group
Group type: COMPARATOR
Intervention: Placebo, plus 200 IU of vitamin E daily
Number of subjects: 29
Study 20837824 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (Actos)
Number of subjects: 29
Study 20837824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 18952945 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-interruptive medication laboratory alerts
Number of subjects: 366
Study 18952945 — intervention group
Group type: COMPARATOR
Intervention: Existing system (control group)
Number of subjects: 366
Study 18952945 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall comparison
Number of subjects: 366
Study 17196292 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Electromagnetic Field (PEMF) therapy
Number of subjects: 80
Study 17196292 — intervention group
Group type: EXPERIMENTAL
Intervention: Spa Therapy (ST)
Number of subjects: 80
Study 17196292 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (Control)
Number of subjects: 80
Study 15471838 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroxine treatment
Number of subjects: 20
Study 15471838 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20
Study 11533267 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone-rich soy (n = 24)
Number of subjects: 69
Study 11533267 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone-poor soy (n = 24)
Number of subjects: 69
Study 11533267 — intervention group
Group type: COMPARATOR
Intervention: Whey control (n = 21)
Number of subjects: 69
Study 11533267 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments combined
Number of subjects: 69
Study 11533267 — intervention group
Group type: EXPERIMENTAL
Intervention: Time effect
Number of subjects: 69
Study 9452150 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrioventricular (AV) delay set at 125 ms
Number of subjects: 12
Study 9452150 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrioventricular (AV) delay set at 100 ms
Number of subjects: 12
Study 9452150 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrioventricular (AV) delay set at 75 ms
Number of subjects: 12
Study 9452150 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrioventricular (AV) delay set at 120 ms (after pacemaker implantation)
Number of subjects: 12
Study 9452150 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrioventricular (AV) delay set at 100 ms (after pacemaker implantation)
Number of subjects: 12
Study 9452150 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrioventricular (AV) delay set at 80 ms (after pacemaker implantation)
Number of subjects: 12
Study 9452150 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in AV delay
Number of subjects: 12
Study 9452150 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of invasive and noninvasive protocols
Number of subjects: 12
Study 7807701 — intervention group
Group type: EXPERIMENTAL
Intervention: Flucytosine (5‐FC) alone
Number of subjects: 60
Study 7807701 — intervention group
Group type: EXPERIMENTAL
Intervention: Flucytosine (5‐FC) in combination with fluconazole (FLCZ) at half doses
Number of subjects: 60
Study 2673478 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐adenosyl methionine (SAM)
Number of subjects: 29
Study 2673478 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 591625 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral L-tryptophan (90 mg/kg BW)
Number of subjects: 8
Study 591625 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31350540 — intervention group
Group type: EXPERIMENTAL
Intervention: N95 respirator usage
Number of subjects: 50
Study 31350540 — intervention group
Group type: COMPARATOR
Intervention: No N95 respirator usage
Number of subjects: 50
Study 31350540 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-roadway exposures
Number of subjects: 50
Study 27164830 — intervention group
Group type: EXPERIMENTAL
Intervention: Human breast milk from preterm infants
Number of subjects: 353
Study 27164830 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined supplementation of preterm infants' BM with choline, ARA, and DHA
Number of subjects: 353
Study 25654562 — intervention group
Group type: EXPERIMENTAL
Intervention: LUS-implemented diagnosis
Number of subjects: 1005
Study 25654562 — intervention group
Group type: COMPARATOR
Intervention: Initial clinical workup
Number of subjects: 1005
Study 25654562 — intervention group
Group type: COMPARATOR
Intervention: Chest radiography alone
Number of subjects: 1005
Study 25654562 — intervention group
Group type: COMPARATOR
Intervention: Natriuretic peptides
Number of subjects: 1005
Study 23677794 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist counseling (n=113)
Number of subjects: 274
Study 23677794 — intervention group
Group type: COMPARATOR
Intervention: Brief 3-minute drug advice (control; n=161)
Number of subjects: 274
Study 20921127 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 738
Study 19953916 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia
Number of subjects: 40
Study 19953916 — intervention group
Group type: COMPARATOR
Intervention: Propofol and remifentanil anesthesia (Group PR)
Number of subjects: 40
Study 16769493 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth-tissue-borne Haas-type expanders
Number of subjects: 8
Study 16769493 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth-borne Hyrax expanders
Number of subjects: 8
Study 15071125 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg of torcetrapib daily
Number of subjects: 19
Study 15071125 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg of torcetrapib twice daily
Number of subjects: 19
Study 15071125 — intervention group
Group type: EXPERIMENTAL
Intervention: Torcetrapib
Number of subjects: 19
Study 9393430 — intervention group
Group type: EXPERIMENTAL
Intervention: Different implant designs
Number of subjects: 2847
Study 9393430 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant designs with higher success rates
Number of subjects: 2847
Study 9393430 — intervention group
Group type: COMPARATOR
Intervention: Surgeons with less experience
Number of subjects: 2847
Study 9393430 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific implant design
Number of subjects: 2847
Study 9393430 — intervention group
Group type: EXPERIMENTAL
Intervention: Study sites
Number of subjects: 2847
Study 8200949 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) low dose (0.4 IU/kg.week)
Number of subjects: 95
Study 8200949 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) high dose (1.2 IU/kg.week)
Number of subjects: 95
Study 8200949 — intervention group
Group type: COMPARATOR
Intervention: Placebo (first 6 months)
Number of subjects: 95
Study 3147809 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10, 20, and 30 mg tid)
Number of subjects: 26
Study 3147809 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (20, 40, and 80 mg tid)
Number of subjects: 26
Study 31940865 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological First Aid (PFA) training
Number of subjects: 129
Study 31940865 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 129
Study 28593365 — intervention group
Group type: EXPERIMENTAL
Intervention: Omission of the bladder flap
Number of subjects: 43
Study 28593365 — intervention group
Group type: COMPARATOR
Intervention: Bladder flap
Number of subjects: 43
Study 28593365 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 43
Study 28742256 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemostatic Sponge with Mastruz (Group SM)
Number of subjects: 36
Study 28742256 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemostatic Sponge (Group HS)
Number of subjects: 36
Study 28742256 — intervention group
Group type: COMPARATOR
Intervention: Blood Clot (Group BC)
Number of subjects: 36
Study 25656696 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-support
Number of subjects: 317
Study 25656696 — intervention group
Group type: EXPERIMENTAL
Intervention: Family/friend support
Number of subjects: 317
Study 25656696 — intervention group
Group type: EXPERIMENTAL
Intervention: Health care support
Number of subjects: 317
Study 24223352 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with lidocaine
Number of subjects: 250
Study 24223352 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprotte needle
Number of subjects: 250
Study 24223352 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of surgery
Number of subjects: 250
Study 24223352 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithotomy position
Number of subjects: 250
Study 21905094 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose vitamin B complex
Number of subjects: 60
Study 21905094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 17678613 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention with personal follow-up instructions
Number of subjects: 0
Study 17678613 — intervention group
Group type: COMPARATOR
Intervention: Intervention with written information only
Number of subjects: 0
Study 16554289 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg for 3 days followed by ER ciprofloxacin 1000 mg
Number of subjects: 27
Study 16554289 — intervention group
Group type: COMPARATOR
Intervention: ER ciprofloxacin 1000 mg
Number of subjects: 27
Study 14653226 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg quazepam administered 2 hours after a meal
Number of subjects: 6
Study 10726786 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005%
Number of subjects: 37
Study 10726786 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5%
Number of subjects: 37
Study 8873541 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil at 1.37 ng/ml
Number of subjects: 220
Study 8873541 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil at 32 ng/ml
Number of subjects: 220
Study 8873541 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane alone (0 ng/ml remifentanil)
Number of subjects: 220
Study 7847597 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol abuse/dependence
Number of subjects: 144
Study 7847597 — intervention group
Group type: COMPARATOR
Intervention: Nonalcoholic depression
Number of subjects: 144
Study 3132055 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine 0.2 mg/kg and midazolam 0.05 mg/kg
Number of subjects: 40
Study 3132055 — intervention group
Group type: COMPARATOR
Intervention: Midazolam 0.05 mg/kg alone
Number of subjects: 40
Study 29224500 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm clothing
Number of subjects: 9
Study 29224500 — intervention group
Group type: COMPARATOR
Intervention: Limited clothing
Number of subjects: 9
Study 28114981 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone
Number of subjects: 687
Study 28114981 — intervention group
Group type: EXPERIMENTAL
Intervention: Mail/Postal
Number of subjects: 687
Study 28114981 — intervention group
Group type: EXPERIMENTAL
Intervention: Email
Number of subjects: 687
Study 24820476 — intervention group
Group type: COMPARATOR
Intervention: Laser acupuncture (Pointer Pulse, 650 nm, 5 mW, 120 s per acupoint)
Number of subjects: 26
Study 24820476 — intervention group
Group type: COMPARATOR
Intervention: Laser acupuncture
Number of subjects: 26
Study 23328189 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan (ARB)
Number of subjects: 16
Study 23328189 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 16
Study 21337043 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB) - two injections of 1.25 mg IVB 6 weeks apart
Number of subjects: 81
Study 21337043 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 81
Study 21337043 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB)
Number of subjects: 81
Study 19351299 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Living Course (HLC) program
Number of subjects: 185
Study 16977739 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant 20 mg/day
Number of subjects: 6500
Study 16977739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6500
Study 16977739 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant
Number of subjects: 6500
Study 12612157 — intervention group
Group type: EXPERIMENTAL
Intervention: TOP/beta-glucan treatment (1.8 g TOP and 2.8 g beta-glucan/d)
Number of subjects: 112
Study 12612157 — intervention group
Group type: COMPARATOR
Intervention: Control foods (similar to treatment but without TOP and beta-glucan)
Number of subjects: 112
Study 12612157 — intervention group
Group type: EXPERIMENTAL
Intervention: TOP/beta-glucan treatment
Number of subjects: 112
Study 12612157 — intervention group
Group type: COMPARATOR
Intervention: Control foods
Number of subjects: 112
Study 10960369 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP at 10 cm H(2)O during CPB
Number of subjects: 14
Study 10960369 — intervention group
Group type: COMPARATOR
Intervention: Control (lungs open to the atmosphere during CPB)
Number of subjects: 14
Study 7597300 — intervention group
Group type: EXPERIMENTAL
Intervention: Excision of primary melanoma with up to 2-mm thickness and 1-cm margins
Number of subjects: 0
Study 7597300 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow excision for melanoma thicker than 2 mm
Number of subjects: 0
Study 7597300 — intervention group
Group type: EXPERIMENTAL
Intervention: Excision of primary tumor
Number of subjects: 0
Study 2253088 — intervention group
Group type: EXPERIMENTAL
Intervention: Natamycin (Tymasil)
Number of subjects: 0
Study 2253088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7313578 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) administration of ampicillin
Number of subjects: 44
Study 7313578 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) administration of ampicillin
Number of subjects: 44